Skip to Content
Merck

Key Documents

View All Documentation

Skip To

L109

Lorglumide sodium salt

solid

Synonym(s):

(±)-4-[(3,4-Dichlorobenzoyl)amino]-5-(dipentylamino)-5-oxopentanoic acid sodium salt, CR 1409

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View
Pack SizeSKUAvailabilityPrice
50 mg
Please contact Customer Service for Availability
CZK 4,080.00
CZK 3,468.00

About This Item

Empirical Formula (Hill Notation):
C22H31Cl2N2NaO4
CAS Number:
1021868-76-7
Molecular Weight:
481.39
NACRES:
NA.32
PubChem Substance ID:
24278098
UNSPSC Code:
12352200
MDL number:
MFCD00083183
Form:
solid
Quality level:
100

CZK 3,468.00

List PriceCZK 4,080.00Save 15%
Please contact Customer Service for Availability
​
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

form

solid

Quality Level

100

color

white

solubility

45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: >10 mg/mL, H2O: 10 mg/mL, methanol: 28 mg/mL

SMILES string

[Na+].CCCCCN(CCCCC)C(=O)C(CCC([O-])=O)NC(=O)c1ccc(Cl)c(Cl)c1

InChI

1S/C22H32Cl2N2O4.Na/c1-3-5-7-13-26(14-8-6-4-2)22(30)19(11-12-20(27)28)25-21(29)16-9-10-17(23)18(24)15-16;/h9-10,15,19H,3-8,11-14H2,1-2H3,(H,25,29)(H,27,28);/q;+1/p-1

InChI key

JCNPYMDDOUQTBK-UHFFFAOYSA-M

Gene Information

human ... CCKAR(886)

Application

Lorglumide sodium salt has been used as a cck-a (cholecystokinin A) receptor antagonist for peptide determination in rat islet cells.[1] It has been used as a CCK1 inhibitor to check the effect of cck1 (cck-a) and cck2 (cck-b) receptors on cerulein-induced upregulation of egr-1 (early growth response 1) expression in rat pancreatic acinar cells.[2]

Biochem/physiol Actions

Potent and selective non-peptide cholecystokinin (CCKA) receptor antagonist; orally active.[3][4]

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item
SML2236SML0130L119
Lorglumide sodium salt solid

Sigma-Aldrich

L109

Lorglumide sodium salt

L-012 sodium salt ≥98% (HPLC)

Sigma-Aldrich

SML2236

L-012 sodium salt

Loxiglumide ≥97% (HPLC)

Sigma-Aldrich

SML0130

Loxiglumide

L-703,606 oxalate salt hydrate solid

Sigma-Aldrich

L119

L-703,606 oxalate salt hydrate

form

solid

form

powder

form

powder

form

solid

Quality Level

100

Quality Level

-

Quality Level

100

Quality Level

100

solubility

45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: >10 mg/mL, methanol: 28 mg/mL, H2O: 10 mg/mL

solubility

H2O: 2 mg/mL, clear

solubility

DMSO: ≥5 mg/mL

solubility

DMSO: >10 mg/mL, 45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 11 mg/mL, H2O: slightly soluble <2 mg/mL

color

white

color

yellow to orange

color

white to beige

color

white

Gene Information

human ... CCKAR(886)

Gene Information

-

Gene Information

-

Gene Information

human ... TACR1(6869)

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCBW5189
BCBW1425
BCBV9486
SLBG5165V
SLBB0576V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

G L Edwards et al.
Annals of the New York Academy of Sciences, 897, 192-197 (2000-02-17)
Ingestion of food and fluid stimulates release of a number of peptides from the gastrointestinal system. These peptides are recognized to act as neurotransmitters/neuromodulators and act at both peripheral and central receptors. Many studies indicate that these peptides are important
H W Suh et al.
Peptides, 16(7), 1229-1234 (1995-01-01)
Various doses of sulfated cholecystokinin octapeptide (CCK-8s) injected intracerebroventricularly (ICV) alone did not show any antinociceptive effect. CCK-8s (0.01-1 ng) pretreated ICV for 10 min dose-dependently attenuated the inhibition of the tail flick response induced by ICV-administered morphine (2 micrograms).
M D'Amato et al.
British journal of pharmacology, 102(2), 391-395 (1991-02-01)
1. Three recently described non-peptide cholecystokinin (CCK) antagonists (devazepide, lorglumide, loxiglumide) have been studied for their antagonism of the contraction to cholecystokinin-octapeptide (CCK-OP) in human alimentary muscle and guinea-pig intestine. 2. Each antagonist caused a concentration-dependent inhibition of the contraction
View All Related Papers

Global Trade Item Number

SKUGTIN
L109-250MG04061832677101
L109-50MG04061832677118

Questions

Reviews

No rating value

Active Filters